What is Arvinas's cash & equivalents?

Arvinas (ARVN) reported cash & equivalents of $87.3M in Q1 2026.

How has Arvinas's cash & equivalents changed year-over-year?

Arvinas's cash & equivalents increased by 7.8% year-over-year, from $81M to $87.3M.

What is the long-term trend for Arvinas's cash & equivalents?

Over 5 years (2020 to 2025), Arvinas's cash & equivalents has grown at a -24.7% compound annual growth rate (CAGR), from $588.4M to $142.9M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Arvinas ARVN Cash & Equivalents

Cash & Equivalents at other companies

Nurix Therapeutics, Inc.NRIX

$72.16M-6.1%

Kymera TherapeuticsKYMR

$144.09M+60.2%

Monte Rosa Therapeutics, Inc.GLUE

$159.86M+104%

Relmada Therapeutics, Inc.RLMD

$9.78M+750%

Nuvectis Pharma, Inc.NVCT

$25.13M-15.9%

ArriVent BioPharma, Inc.AVBP

$62.1M+24.5%

Other financials

Income statement

See full

Revenue$15.6M-91.7%

Operating income-$63.8M-189%

Net income-$57.6M-169%

EPS (diluted)-$0.90-179%

Balance sheet

See full

Total debt$8.6M-19.6%

Total equity$386.8M-41.4%

Total assets$647.5M-35.3%

Cash flow

See full

Operating cash flow-$69.2M+22.2%

CapEx$1.3M+225%

Free cash flow-$70.5M+21.1%

Valuation

See full

Market cap$518.11M-4.6%

Enterprise value$439.41M-7.1%

P/S5.8×+4.5×

Profitability

See full

Operating margin-283.8%-310pp

Net margin-247.5%-260pp

FCF margin-287.4%—

Returns & leverage

See full

Return on equity-42.3%-53.5pp

Debt / equity0×0.0×

Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arvinas's cash & equivalents?: Arvinas (ARVN) reported cash & equivalents of $87.3M in Q1 2026.
How has Arvinas's cash & equivalents changed year-over-year?: Arvinas's cash & equivalents increased by 7.8% year-over-year, from $81M to $87.3M.
What is the long-term trend for Arvinas's cash & equivalents?: Over 5 years (2020 to 2025), Arvinas's cash & equivalents has grown at a -24.7% compound annual growth rate (CAGR), from $588.4M to $142.9M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.